Dayer J M, Fenner H
Baillieres Clin Rheumatol. 1992 Jun;6(2):485-516. doi: 10.1016/s0950-3579(05)80186-4.
The role of cytokines in inflammatory joint diseases is well documented, especially with regard to tissue destruction and remodelling. In these processes, IL-1 and TNF alpha play a prominent part by stimulating protease production. The regulation of their production, their release and their effects on target cells (e.g. synovial cells, chondrocytes and bone-derived cells) has therefore been the subject of intensive investigations. In this context a new dimension has emerged recently due to the observation of the existence of natural specific cytokine inhibitors. IL-1-ra and the soluble fragments of both TNF receptors--inhibitory by binding to TNF alpha--are natural products. These appear to be the molecules best suited for controlling the imbalance between pro- and anti-inflammatory processes. The use of the recombinant forms of these inhibitors may open new perspectives for therapeutic intervention. The fact that the respective mechanisms of action of receptor antagonists and inhibitory binding proteins differ does not rule out their complementarity. Preliminary experiments with animal models have yielded promising results which should be followed up by clinical trials.
细胞因子在炎性关节疾病中的作用已有充分记载,尤其是在组织破坏和重塑方面。在这些过程中,白细胞介素-1(IL-1)和肿瘤坏死因子α(TNFα)通过刺激蛋白酶产生发挥重要作用。因此,对它们的产生、释放及其对靶细胞(如滑膜细胞、软骨细胞和骨源性细胞)的影响的调控一直是深入研究的课题。在这方面,由于发现了天然特异性细胞因子抑制剂,最近出现了一个新的层面。IL-1受体拮抗剂(IL-1-ra)以及两种肿瘤坏死因子受体的可溶性片段——通过与TNFα结合而具有抑制作用——都是天然产物。这些似乎是最适合控制促炎和抗炎过程之间失衡的分子。使用这些抑制剂的重组形式可能为治疗干预开辟新的前景。受体拮抗剂和抑制性结合蛋白各自的作用机制不同,但这并不排除它们的互补性。动物模型的初步实验已取得了有希望的结果,后续应进行临床试验。